The CAM-I mechanism is new, and there is still a lot we do not know or how it will develop. To our current knowledge, CAM-I inhibitors would not affect cccDNA. However, these compounds are HBV RNaseH inhibitors (with a secondary effect on capsids), and we know that RNaseH inhibitors can prevent cccDNA formation.
These inhibitors are expected to be used with others like nucleoside analogs (Lamivudine, Entecavir, etc.), likely as part of a management regime or combinatorial treatment. However, the identification of this new mechanism could help us find new types of capsid-targeting inhibitors.